Page 3 - Nasdaq Phvs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

Pharvaris (NASDAQ:PHVS – Get Free Report)’s share price rose 4.9% during mid-day trading on Friday . The company traded as high as $21.50 and last traded at $21.50. Approximately 3,412 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 45,482 shares. The stock had previously closed at $20.50. […]

Morgan Stanley upgraded shares of Pharvaris (NASDAQ:PHVS – Free Report) from an equal weight rating to an overweight rating in a research report released on Tuesday morning, MarketBeat Ratings reports. The firm currently has $34.00 price objective on the stock, up from their previous price objective of $10.00. Pharvaris Stock Down 5.4 % Shares of […]

Morgan Stanley upgraded shares of Pharvaris (NASDAQ:PHVS – Free Report) from an equal weight rating to an overweight rating in a research note released on Tuesday morning, MarketBeat.com reports. The firm currently has $34.00 target price on the stock, up from their previous target price of $10.00. Pharvaris Stock Performance PHVS opened at $19.32 on […]

Morgan Stanley reaffirmed their equal weight rating on shares of Pharvaris (NASDAQ:PHVS – Free Report) in a research report sent to investors on Monday, Benzinga reports. Morgan Stanley currently has a $10.00 price target on the stock. Separately, JMP Securities lowered their target price on shares of Pharvaris from $23.00 to $20.00 and set a […]